His executive experience spans global industry leaders including Abbott Diagnostics, Roche Molecular Diagnostics, and LifeTechnologies/Thermo Fisher, as well as public CEO roles at Clarient Inc and ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

focusing on stocks such as Roche Holding AG, Sanofi, and Molecular Partners AG. According to TipRanks, Vosser has an average return of 5.0% and a 49.18% success rate on recommended stocks. Merck KGaA ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

Argonne National Laboratory, Flagship Pioneering, Terray, Weights & Biases and Dozens More Organizations Among Contributors ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.

The study of cell invasion and migration is of great importance to enable a better understanding of underlying biological and molecular mechanisms. The new CIM-Plate 16 device from Roche Applied ...